FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* CHEN JIN-LONG					<u>NG</u>	2. Issuer Name and Ticker or Trading Symbol NGM BIOPHARMACEUTICALS INC [NGM]									all app		ng Pers	10% O	wner
(Last)	_ast) (First) (Middle) 33 OYSTER POINT BOULEVARD						Date of Earliest Transaction (Month/Day/Year)								X Officer (give title below) Other below Chief Scientific Officer				specify
(Street) SOUTH SAN FRANCISCO CA 94080 (City) (State) (Zip)						10/12/2020 4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Table	I - No	on-Deriva	tive S	Secui	rities	Acc	quired	l, Dis	posed of	, or E	Benefic	ially	Own	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/					Executi Year) if any		ition Date,		3. Transaction Code (Instr. 8)				and 5) Securi		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) o (D)	Price	Trai		action(s) 3 and 4)			(111341. 4)
Common Stock 10/12/20					020				S ⁽¹⁾		25,000	D	\$17.)2 ⁽²⁾ 945,0		15,005		D	
		Tal	ole II						,		osed of, convertib			•	Owne	d			
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, urity or Exercise (Month/Day/Year) if any			4. Transaction Code (Instr. 8)		of	r r osed) r. 3, 4	6. Date Expira (Monti	tion D	Year) Secui Unde Deriva		int of rities rlying ative rity (Instr. 4)	Deri Sec (Ins	rice of ivative urity tr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y D o (I	0. Ownership Form: Direct (D) or Indirect I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amount or Number of Shares						

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2020.
- 2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$16.79 to \$17.46. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

10/13/2020

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.